secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001077183-25-000145
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board
--------------------------------------------------------------------

- Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.
- Dr. Green is SVP and Head of Oncology, Global Clinical Development at Merck, leading oncology R&D for Merck's largest revenue area.
- Prior leadership roles include SVP Late-Stage Development at Seagen and VP at Genentech; began career as medical oncologist at MD Anderson.
- She will serve as an independent director until the 2026 annual meeting; compensation follows standard director program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000145/0001077183-25-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000145/neo-20250619.htm
  HTML page:      https://secwatch.observer/filing/0001077183-25-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer